Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2024

Open Access 01-12-2024 | Glioblastoma | Review

New insights into targeted therapy of glioblastoma using smart nanoparticles

Authors: Habib Ghaznavi, Reza Afzalipour, Samideh Khoei, Saman Sargazi, Sakine Shirvalilou, Roghayeh Sheervalilou

Published in: Cancer Cell International | Issue 1/2024

Login to get access

Abstract

In recent times, the intersection of nanotechnology and biomedical research has given rise to nanobiomedicine, a captivating realm that holds immense promise for revolutionizing diagnostic and therapeutic approaches in the field of cancer. This innovative fusion of biology, medicine, and nanotechnology aims to create diagnostic and therapeutic agents with enhanced safety and efficacy, particularly in the realm of theranostics for various malignancies. Diverse inorganic, organic, and hybrid organic–inorganic nanoparticles, each possessing unique properties, have been introduced into this domain. This review seeks to highlight the latest strides in targeted glioblastoma therapy by focusing on the application of inorganic smart nanoparticles. Beyond exploring the general role of nanotechnology in medical applications, this review delves into groundbreaking strategies for glioblastoma treatment, showcasing the potential of smart nanoparticles through in vitro studies, in vivo investigations, and ongoing clinical trials.
Literature
1.
Barnholtz-Sloan JS, Ostrom QT, Cote D. Epidemiology of brain tumors. Neurol Clin. 2018;36(3):395–419.PubMedCrossRef
2.
Ostrom QT, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014–2018. Neuro-oncology. 2021;23(Supplement_3):iii1–iii105.
3.
4.
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng H, Pfister SM, Reifenberger G. The 2021 WHO classification of tumors of the central nervous system: a summary. Neurooncology. 2021;23(8):1231–51.
5.
Lu G, Wang X, Li F, Wang S, Zhao J, Wang J, Liu J, Lyu C, Ye P, Tan H. Engineered biomimetic nanoparticles achieve targeted delivery and efficient metabolism-based synergistic therapy against glioblastoma. Nat Commun. 2022;13(1):1–17.
6.
Akhter MH, Rizwanullah M, Ahmad J, Amin S, Ahmad MZ, Minhaj MA, Mujtaba MA, Ali J. Molecular targets and nanoparticulate systems designed for the improved therapeutic intervention in glioblastoma multiforme. Drug Res. 2021;71(03):122–37.CrossRef
7.
Janjua TI, Rewatkar P, Ahmed-Cox A, Saeed I, Mansfeld FM, Kulshreshtha R, Kumeria T, Ziegler DS, Kavallaris M, Mazzieri R. Frontiers in the treatment of glioblastoma: past, present and emerging. Adv Drug Deliv Rev. 2021;171:108–38.PubMedCrossRef
8.
Tan AC, Ashley DM, López GY, Malinzak M, Friedman HS, Khasraw M. Management of glioblastoma: state of the art and future directions. Cancer J Clin. 2020;70(4):299–312.CrossRef
9.
Cote DJ, Ostrom QT. Epidemiology and etiology of glioblastoma. Precision Mol Pathol Glioblastoma. 2021:3–19.
10.
Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014. Neurooncology. 2017;19(suppl5):v1–88.
11.
Walker EV, Davis FG, Bryant Heather CfaSALRSLWRKCSJGM-CPJMBB-SJTDKMHH. : Malignant primary brain and other central nervous system tumors diagnosed in Canada from 2009 to 2013. Neuro-oncology. 2019;21(3):360–369.
12.
Fabbro-Peray P, Zouaoui S, Darlix A, Fabbro M, Pallud J, Rigau V, Mathieu-Daude H, Bessaoud F, Bauchet F, Riondel A. Association of patterns of care, prognostic factors, and use of radiotherapy–temozolomide therapy with survival in patients with newly diagnosed glioblastoma: a French national population-based study. J Neurooncol. 2019;142(1):91–101.PubMedCrossRef
13.
Gittleman H, Boscia A, Ostrom QT, Truitt G, Fritz Y, Kruchko C, Barnholtz-Sloan JS. Survivorship in adults with malignant brain and other central nervous system tumor from 2000–2014. Neuro-oncology. 2018;20(suppl_7):vii6’vii16.
14.
Brodbelt A, Greenberg D, Winters T, Williams M, Vernon S, Collins VP. Glioblastoma in England: 2007–2011. Eur J Cancer. 2015;51(4):533–42.PubMedCrossRef
15.
Simińska D, Korbecki J, Kojder K, Kapczuk P, Fabiańska M, Gutowska I, Machoy-Mokrzyńska A, Chlubek D, Baranowska-Bosiacka I. Epidemiology of anthropometric factors in glioblastoma multiforme—literature review. Brain Sci. 2021;11(1):116.PubMedPubMedCentralCrossRef
16.
Cuschieri A, Pisani R, Agius S. From trauma to tumour: exploring post-TBI glioblastoma patient characteristics. World Neurosurg. 2024.
17.
Louis DN, Perry A, Reifenberger G, Von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–20.PubMedCrossRef
18.
Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98–110.PubMedPubMedCentralCrossRef
19.
Wang Q, Hu B, Hu X, Kim H, Squatrito M, Scarpace L, DeCarvalho AC, Lyu S, Li P, Li Y. Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment. Cancer Cell. 2017;32(1):42–56. e46.PubMedPubMedCentralCrossRef
20.
Gonzalez Castro LN, Wesseling P. The cIMPACT-NOW updates and their significance to current neuro-oncology practice. Neuro-Oncology Pract. 2021;8(1):4–10.CrossRef
21.
Czarnywojtek A, Borowska M, Dyrka K, Van Gool S, Sawicka-Gutaj N, Moskal J, Kościński J, Graczyk P, Hałas T, Lewandowska AM. Glioblastoma multiforme: the latest diagnostics and treatment techniques. Pharmacology. 2023;108(5):423–31.PubMedCrossRef
22.
23.
Sheervalilou R, Shirvaliloo S, Fekri Aval S, Khamaneh AM, Sharifi A, Ansarin K, Zarghami N. A new insight on reciprocal relationship between microRNA expression and epigenetic modifications in human lung cancer. Tumor Biology. 2017;39(5):1010428317695032.PubMedCrossRef
24.
Wu W, Klockow JL, Zhang M, Lafortune F, Chang E, Jin L, Wu Y, Daldrup-Link HE. Glioblastoma multiforme (GBM): an overview of current therapies and mechanisms of resistance. Pharmacol Res. 2021;171:105780.PubMedPubMedCentralCrossRef
25.
Ulutin C, Fayda M, Aksu G, Cetinayak O, Kuzhan O, Ors F, Beyzadeoglu M. Primary glioblastoma multiforme in younger patients: a single-institution experience. Tumori J. 2006;92(5):407–11.CrossRef
26.
Jung C, Foerch C, Schänzer A, Heck A, Plate K, Seifert V, Steinmetz H, Raabe A, Sitzer M. Serum GFAP is a diagnostic marker for glioblastoma multiforme. Brain. 2007;130(12):3336–41.PubMedCrossRef
27.
Stupp R, Hegi ME, Gilbert MR, Chakravarti A. Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol. 2007;25(26):4127–36.PubMedCrossRef
28.
Liu S, Shi W, Zhao Q, Zheng Z, Liu Z, Meng L, Dong L, Jiang X. Progress and prospect in tumor treating fields treatment of glioblastoma. Biomed Pharmacother. 2021;141:111810.PubMedCrossRef
29.
30.
Hernández-Pedro NY, Rangel-López E, Magaña-Maldonado R, de la Cruz VP, Santamaría, del Angel A, Pineda B, Sotelo J. Application of nanoparticles on diagnosis and therapy in gliomas. BioMed Res Int. 2013;2013.
31.
Neska-Matuszewska M, Bladowska J, Sąsiadek M, Zimny A. Differentiation of glioblastoma multiforme, metastases and primary central nervous system lymphomas using multiparametric perfusion and diffusion MR imaging of a tumor core and a peritumoral zone—searching for a practical approach. PLoS ONE. 2018;13(1):e0191341.PubMedPubMedCentralCrossRef
32.
Shergalis A, Bankhead A, Luesakul U, Muangsin N, Neamati N. Current challenges and opportunities in treating glioblastoma. Pharmacol Rev. 2018;70(3):412–45.PubMedPubMedCentralCrossRef
33.
Sheervalilou R, Shirvaliloo M, Sargazi S, Ghaznavi H. Recent advances in iron oxide nanoparticles for brain cancer theranostics: from in vitro to clinical applications. Expert Opin Drug Deliv. 2021;18(7):949–77.PubMedCrossRef
34.
35.
Ljubimova JY, Sun T, Mashouf L, Ljubimov AV, Israel LL, Ljubimov VA, Falahatian V, Holler E. Covalent nano delivery systems for selective imaging and treatment of brain tumors. Adv Drug Deliv Rev. 2017;113:177–200.PubMedPubMedCentralCrossRef
36.
Danhier F. To exploit the tumor microenvironment: since the EPR effect fails in the clinic, what is the future of nanomedicine? J Controlled Release. 2016;244:108–21.CrossRef
37.
Urbantat RM, Jelgersma C, Brandenburg S, Nieminen-Kelhä M, Kremenetskaia I, Zollfrank J, Mueller S, Rubarth K, Koch A, Vajkoczy P. Tumor-associated microglia/macrophages as a predictor for survival in glioblastoma and temozolomide-induced changes in CXCR2 signaling with new resistance overcoming strategy by combination therapy. Int J Mol Sci. 2021;22(20):11180.PubMedPubMedCentralCrossRef
38.
Zhao M, van Straten D, Broekman ML, Préat V, Schiffelers RM. Nanocarrier-based drug combination therapy for glioblastoma. Theranostics. 2020;10(3):1355.PubMedPubMedCentralCrossRef
39.
Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D. Bevacizumab plus radiotherapy–temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709–22.PubMedCrossRef
40.
Cheng Z, Li M, Dey R, Chen Y. Nanomaterials for cancer therapy: current progress and perspectives. J Hematol Oncol. 2021;14(1):1–27.CrossRef
41.
42.
Ozdemir-Kaynak E, Qutub AA, Yesil-Celiktas O. Advances in glioblastoma multiforme treatment: new models for nanoparticle therapy. Front Physiol. 2018;9:170.PubMedPubMedCentralCrossRef
43.
Gevertz JL, Gillies GT, Torquato S. Simulating tumor growth in confined heterogeneous environments. Phys Biol. 2008;5(3):036010.PubMedCrossRef
44.
Escribá PV, Busquets X, Inokuchi J-i, Balogh G, Török Z, Horváth I, Harwood JL, Vígh L. Membrane lipid therapy: modulation of the cell membrane composition and structure as a molecular base for drug discovery and new disease treatment. Prog Lipid Res. 2015;59:38–53.PubMedCrossRef
45.
Watanabe Y, Dahlman EL, Leder KZ, Hui SK. A mathematical model of tumor growth and its response to single irradiation. Theoretical Biology Med Modelling. 2016;13:1–20.CrossRef
46.
Gevertz JL. Computational modeling of tumor response to vascular-targeting therapies—part I: validation. Comput Math Method M. 2011;2011.
47.
Alfonso JCL, Köhn-Luque A, Stylianopoulos T, Feuerhake F, Deutsch A, Hatzikirou H. Why one-size-fits-all vaso-modulatory interventions fail to control glioma invasion: in silico insights. Sci Rep. 2016;6(1):37283.PubMedPubMedCentralCrossRef
48.
Lauzon M-A, Daviau A, Marcos B, Faucheux N. Nanoparticle-mediated growth factor delivery systems: a new way to treat Alzheimer’s disease. J Controlled Release. 2015;206:187–205.CrossRef
49.
Wang Z, Gao L, Guo X, Feng C, Lian W, Deng K, Xing B. Development and validation of a nomogram with an autophagy-related gene signature for predicting survival in patients with glioblastoma. Aging. 2019;11(24):12246.PubMedPubMedCentralCrossRef
50.
Sheervalilou R, Khamaneh AM, Sharifi A, Nazemiyeh M, Taghizadieh A, Ansarin K, Zarghami N. Using miR-10b, miR-1 and miR-30a expression profiles of bronchoalveolar lavage and sputum for early detection of non-small cell lung cancer. Biomed Pharmacother. 2017;88:1173–82.CrossRef
51.
52.
53.
Chaturvedi VK, Singh A, Singh VK, Singh MP. Cancer nanotechnology: a new revolution for cancer diagnosis and therapy. Curr Drug Metab. 2019;20(6):416–29.PubMedCrossRef
54.
Zottel A, Videtič Paska A, Jovčevska I. Nanotechnology meets oncology: nanomaterials in brain cancer research, diagnosis and therapy. Materials. 2019;12(10):1588.PubMedPubMedCentralCrossRef
55.
Almanghadim HG, Nourollahzadeh Z, Khademi NS, Tezerjani MD, Sehrig FZ, Estelami N, Shirvaliloo M, Sheervalilou R, Sargazi S. Application of nanoparticles in cancer therapy with an emphasis on cell cycle. Cell Biol Int. 2021;45(10):1989–98.PubMedCrossRef
56.
57.
Jayasinghe MK, Tan M, Peng B, Yang Y, Sethi G, Pirisinu M, Le MT. New approaches in extracellular vesicle engineering for improving the efficacy of anti-cancer therapies. In: Seminars in Cancer Biology: 2021. Elsevier: 62–78.
58.
Shahraki K, Boroumand PG, Lotfi H, Radnia F, Shahriari H, Sargazi S, Mortazavi SS, Shirvaliloo M, Shirvalilou S, Sheervalilou R. An update in the applications of exosomes in cancer theranostics: from research to clinical trials. J Cancer Res Clin Oncol. 2023:1–30.
59.
Peer D, Karp J, Hong S, Farokhzad O, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotech. 2007;2(2007):751–759.
60.
Gaillard PJ, Appeldoorn CC, Rip J, Dorland R, van der Pol SM, Kooij G, de Vries HE, Reijerkerk A. Enhanced brain delivery of liposomal methylprednisolone improved therapeutic efficacy in a model of neuroinflammation. J Controlled Release. 2012;164(3):364–9.CrossRef
61.
Gaillard PJ, Appeldoorn CC, Dorland R, Van Kregten J, Manca F, Vugts DJ, Windhorst B, van Dongen GA, de Vries HE, Maussang D. Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101). PLoS ONE. 2014;9(1):e82331.PubMedPubMedCentralCrossRef
62.
63.
64.
Zois CE, Harris AL. Glycogen metabolism has a key role in the cancer microenvironment and provides new targets for cancer therapy. J Mol Med. 2016;94(2):137–54.PubMedCrossRef
65.
Song W, Anselmo AC, Huang L. Nanotechnology intervention of the microbiome for cancer therapy. Nat Nanotechnol. 2019;14(12):1093–103.PubMedCrossRef
66.
Telrandhe R. Nanotechnology for cancer therapy: recent developments. Eur J Pharm Med Res. 2016;3(11):284–94.
67.
Farokhzad OC, Jon S, Khademhosseini A, Tran T-NT, LaVan DA, Langer R. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res. 2004;64(21):7668–72.PubMedCrossRef
68.
Karabeber H, Huang R, Iacono P, Samii JM, Pitter K, Holland EC, Kircher MF. Guiding brain tumor resection using surface-enhanced Raman scattering nanoparticles and a hand-held Raman scanner. ACS Nano. 2014;8(10):9755–66.PubMedPubMedCentralCrossRef
69.
Rutka JT, Kim B, Etame A, Diaz RJ. Nanosurgical resection of malignant brain tumors: beyond the cutting edge. ACS Nano. 2014;8(10):9716–22.PubMedCrossRef
70.
Chatterjee P, Kumar S. Current developments in nanotechnology for cancer treatment. Mater Today: Proc. 2022;48:1754–8.
71.
Martin F, Melnik K, West T, Shapiro J, Cohen M, Boiarski A, Ferrari M. Acute toxicity of intravenously administered microfabricated silicon dioxide drug delivery particles in mice: preliminary findings. Drugs R D. 2005;6:71–81.PubMedCrossRef
72.
Loo C, Lowery A, Halas N, West J, Drezek R. Immunotargeted nanoshells for integrated cancer imaging and therapy. Nano Lett. 2005;5(4):709–11.PubMedCrossRef
73.
Green JJ, Chiu E, Leshchiner ES, Shi J, Langer R, Anderson DG. Electrostatic ligand coatings of nanoparticles enable ligand-specific gene delivery to human primary cells. Nano Lett. 2007;7(4):874–9.PubMedCrossRef
74.
Pan B, Cui D, Sheng Y, Ozkan C, Gao F, He R, Li Q, Xu P, Huang T. Dendrimer-modified magnetic nanoparticles enhance efficiency of gene delivery system. Cancer Res. 2007;67(17):8156–63.PubMedCrossRef
75.
Mohanraj V, Chen Y. Nanoparticles-a review. Trop J Pharm Res. 2006;5(1):561–73.
76.
Yan F, Xu H, Anker J, Kopelman R, Ross B, Rehemtulla A, Reddy R. Synthesis and characterization of silica-embedded iron oxide nanoparticles for magnetic resonance imaging. J Nanosci Nanotechnol. 2004;4(1–2):72–6.PubMedCrossRef
77.
Palazzolo S, Bayda S, Hadla M, Caligiuri I, Corona G, Toffoli G, Rizzolio F. The clinical translation of organic nanomaterials for cancer therapy: a focus on polymeric nanoparticles, micelles, liposomes and exosomes. Curr Med Chem. 2018;25(34):4224–68.PubMedCrossRef
78.
Liu J, Huang J, Zhang L, Lei J. Multifunctional metal–organic framework heterostructures for enhanced cancer therapy. Chem Soc Rev. 2021;50(2):1188–218.PubMedCrossRef
79.
Wang D, Zhang Z, Lin L, Liu F, Wang Y, Guo Z, Li Y, Tian H, Chen X. Porphyrin-based covalent organic framework nanoparticles for photoacoustic imaging-guided photodynamic and photothermal combination cancer therapy. Biomaterials. 2019;223:119459.PubMedCrossRef
80.
81.
Xiao W, Ehsanipour A, Sohrabi A, Seidlits SK. Hyaluronic-acid based hydrogels for 3-dimensional culture of patient-derived glioblastoma cells. JoVE (Journal Visualized Experiments). 2018(138):e58176.
82.
Lapcık L Jr, Lapcık L, De Smedt S, Demeester J, Chabrecek P. Hyaluronan: preparation, structure, properties, and applications. Chem Rev. 1998;98(8):2663–84.PubMedCrossRef
83.
Cai Z, Zhang H, Wei Y, Cong F. Hyaluronan-inorganic nanohybrid materials for biomedical applications. Biomacromolecules. 2017;18(6):1677–96.PubMedCrossRef
84.
Mattheolabakis G, Rigas B, Constantinides PP. Nanodelivery strategies in cancer chemotherapy: biological rationale and pharmaceutical perspectives. Nanomedicine. 2012;7(10):1577–90.PubMedCrossRef
85.
86.
Li M, Luo Z, Zhao Y. Recent advancements in 2D nanomaterials for cancer therapy. Sci China Chem. 2018;61(10):1214–26.CrossRef
87.
Fei W, Zhang M, Fan X, Ye Y, Zhao M, Zheng C, Li Y, Zheng X. Engineering of bioactive metal sulfide nanomaterials for cancer therapy. J Nanobiotechnol. 2021;19(1):1–27.CrossRef
88.
Wiwatchaitawee K, Quarterman JC, Geary SM, Salem AK. Enhancement of therapies for glioblastoma (GBM) using nanoparticle-based delivery systems. AAPS PharmSciTech. 2021;22:1–16.CrossRef
89.
90.
Jain K. Nanobiotechnology-based drug delivery to the central nervous system. Neurodegenerative Dis. 2007;4(4):287–91.CrossRef
91.
Tran S, DeGiovanni P-J, Piel B, Rai P. Cancer nanomedicine: a review of recent success in drug delivery. Clin Translational Med. 2017;6(1):1–21.CrossRef
92.
Ganipineni LP, Danhier F, Préat V. Drug delivery challenges and future of chemotherapeutic nanomedicine for glioblastoma treatment. J Controlled Release. 2018;281:42–57.CrossRef
93.
Giese A, Bjerkvig R, Berens M, Westphal M. Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol. 2003;21(8):1624–36.PubMedCrossRef
94.
Tzeng SY, Green JJ. Therapeutic nanomedicine for brain cancer. Therapeutic Delivery. 2013;4(6):687–704.PubMedCrossRef
95.
Karthika C, Sureshkumar R, Zehravi M, Akter R, Ali F, Ramproshad S, Mondal B, Kundu MK, Dey A, Rahman M. Multidrug resistance in cancer cells: focus on a possible strategy plan to address colon carcinoma cells. Life. 2022;12(6):811.PubMedPubMedCentralCrossRef
96.
Marin J, Al-Abdulla R, Lozano E, Briz O, Bujanda L, Banales M, Macias J. Mechanisms of resistance to chemotherapy in gastric cancer. Anti-Cancer Agents Med Chem (Formerly Curr Med Chemistry-Anti-Cancer Agents). 2016;16(3):318–34.
97.
Majidinia M, Mirza-Aghazadeh‐Attari M, Rahimi M, Mihanfar A, Karimian A, Safa A, Yousefi B. Overcoming multidrug resistance in cancer: recent progress in nanotechnology and new horizons. IUBMB Life. 2020;72(5):855–71.PubMedCrossRef
98.
Xu Y-Y, Gao P, Sun Y, Duan Y-R. Development of targeted therapies in treatment of glioblastoma. Cancer Biology Med. 2015;12(3):223.
99.
Jurj A, Braicu C, Pop L-A, Tomuleasa C, Gherman CD, Berindan-Neagoe I. The new era of nanotechnology, an alternative to change cancer treatment. Drug Des Devel Ther. 2017;11:2871.PubMedPubMedCentralCrossRef
100.
Jallouli Y, Paillard A, Chang J, Sevin E, Betbeder D. Influence of surface charge and inner composition of porous nanoparticles to cross blood–brain barrier in vitro. Int J Pharm. 2007;344(1–2):103–9.PubMedCrossRef
101.
Li S-D, Huang L. Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. Biochim et Biophys Acta (BBA)-Biomembranes. 2009;1788(10):2259–66.PubMedCrossRef
102.
Zhao J, Zhang B, Shen S, Chen J, Zhang Q, Jiang X, Pang Z. CREKA peptide-conjugated dendrimer nanoparticles for glioblastoma multiforme delivery. J Colloid Interface Sci. 2015;450:396–403.PubMedCrossRef
103.
Gref R, Domb A, Quellec P, Blunk T, Müller R, Verbavatz J-M, Langer R. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv Drug Deliv Rev. 1995;16(2–3):215–33.PubMedPubMedCentralCrossRef
104.
Laginha KM, Verwoert S, Charrois GJ, Allen TM. Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clin Cancer Res. 2005;11(19):6944–9.PubMedCrossRef
105.
Tagde P, Tagde P, Tagde S, Bhattacharya T, Garg V, Akter R, Rahman MH, Najda A, Albadrani GM, Sayed AA. Natural bioactive molecules: an alternative approach to the treatment and control of glioblastoma multiforme. Biomed Pharmacother. 2021;141:111928.PubMedCrossRef
106.
Huang H, Feng W, Chen Y, Shi J. Inorganic nanoparticles in clinical trials and translations. Nano Today. 2020;35:100972.CrossRef
107.
Li X, Li W, Wang M, Liao Z. Magnetic nanoparticles for cancer theranostics: advances and prospects. J Controlled Release. 2021;335:437–48.CrossRef
108.
Farzin A, Etesami SA, Quint J, Memic A, Tamayol A. Magnetic nanoparticles in cancer therapy and diagnosis. Adv Healthc Mater. 2020;9(9):1901058.CrossRef
109.
110.
Pourgholi F, Farhad J-N, Kafil HS, Yousefi M. Nanoparticles: novel vehicles in treatment of glioblastoma. Biomed Pharmacother. 2016;77:98–107.PubMedCrossRef
111.
Rezaie P, Khoei S, Khoee S, Shirvalilou S, Mahdavi SR. Evaluation of combined effect of hyperthermia and ionizing radiation on cytotoxic damages induced by IUdR-loaded PCL-PEG-coated magnetic nanoparticles in spheroid culture of U87MG glioblastoma cell line. Int J Radiat Biol. 2018;94(11):1027–37.PubMedCrossRef
112.
Campos EA, Pinto DVBS, Oliveira, JISd. Mattos EdC, Dutra RdCL: synthesis, characterization and applications of iron oxide nanoparticles-a short review. J Aerosp Technol Manage. 2015;7:267–76.CrossRef
113.
Assa F, Jafarizadeh-Malmiri H, Ajamein H, Anarjan N, Vaghari H, Sayyar Z, Berenjian A. A biotechnological perspective on the application of iron oxide nanoparticles. Nano Res. 2016;9(8):2203–25.CrossRef
114.
Akbarzadeh A, Samiei M, Davaran S. Magnetic nanoparticles: preparation, physical properties, and applications in biomedicine. Nanoscale Res Lett. 2012;7(1):1–13.CrossRef
115.
Li F, Lu J, Kong X, Hyeon T, Ling D. Dynamic nanoparticle assemblies for biomedical applications. Adv Mater. 2017;29(14):1605897.CrossRef
116.
Arias LS, Pessan JP, Vieira APM, Lima TMTd, Delbem ACB, Monteiro DR. Iron oxide nanoparticles for biomedical applications: a perspective on synthesis, drugs, antimicrobial activity, and toxicity. Antibiotics. 2018;7(2):46.PubMedPubMedCentralCrossRef
117.
Bruschi ML, de Toledo LAS. Pharmaceutical applications of iron-oxide magnetic nanoparticles. Magnetochemistry. 2019;5(3):50.CrossRef
118.
Alexiou C, Schmid RJ, Jurgons R, Kremer M, Wanner G, Bergemann C, Huenges E, Nawroth T, Arnold W, Parak FG. Targeting cancer cells: magnetic nanoparticles as drug carriers. Eur Biophys J. 2006;35(5):446–50.PubMedCrossRef
119.
Abadi B, Yazdanpanah N, Nokhodchi A, Rezaei N. Smart biomaterials to enhance the efficiency of immunotherapy in glioblastoma: state of the art and future perspectives. Adv Drug Deliv Rev. 2021;179:114035.PubMedCrossRef
120.
Ciccarese F, Raimondi V, Sharova E, Silic-Benussi M, Ciminale V. Nanoparticles as tools to target redox homeostasis in cancer cells. Antioxidants. 2020;9(3):211.PubMedPubMedCentralCrossRef
121.
Jin J, Ovais M, Chen C. Stimulus-responsive gold nanotheranostic platforms for targeting the tumor microenvironment. Nano Today. 2018;22:83–99.CrossRef
122.
Singh P, Pandit S, Mokkapati V, Garg A, Ravikumar V, Mijakovic I. Gold nanoparticles in diagnostics and therapeutics for human cancer. Int J Mol Sci. 2018;19(7):1979.PubMedPubMedCentralCrossRef
123.
Aryal S, Bisht G. New paradigm for a targeted cancer therapeutic approach: a short review on potential synergy of gold nanoparticles and cold atmospheric plasma. Biomedicines. 2017;5(3):38.PubMedPubMedCentralCrossRef
124.
Rehman Y, Qutaish H, Kim JH, Huang X-F, Alvi S, Konstantinov K. Microenvironmental behaviour of nanotheranostic systems for controlled oxidative stress and cancer treatment. Nanomaterials. 2022;12(14):2462.PubMedPubMedCentralCrossRef
125.
Chen N, Yang W, Bao Y, Xu H, Qin S, Tu Y. BSA capped au nanoparticle as an efficient sensitizer for glioblastoma tumor radiation therapy. RSC Adv. 2015;5(51):40514–20.CrossRef
126.
Peng L, Liang Y, Zhong X, Liang Z, Tian Y, Li S, Liang J, Wang R, Zhong Y, Shi Y. Aptamer-conjugated gold nanoparticles targeting epidermal growth factor receptor variant III for the treatment of glioblastoma. Int J Nanomed. 2020;15:1363.CrossRef
127.
128.
Saleem J, Wang L, Chen C. Carbon-based nanomaterials for cancer therapy via targeting tumor microenvironment. Adv Healthc Mater. 2018;7(20):1800525.CrossRef
129.
Leite ML, da Cunha NB, Costa FF. Antimicrobial peptides, nanotechnology, and natural metabolites as novel approaches for cancer treatment. Pharmacol Ther. 2018;183:160–76.PubMedCrossRef
130.
Chakrabarti M, Kiseleva R, Vertegel A, Ray SK. Carbon nanomaterials for drug delivery and cancer therapy. J Nanosci Nanotechnol. 2015;15(8):5501–11.PubMedCrossRef
131.
Benos L, Spyrou LA, Sarris IE. Development of a new theoretical model for blood-CNTs effective thermal conductivity pertaining to hyperthermia therapy of glioblastoma multiform. Comput Methods Programs Biomed. 2019;172:79–85.PubMedCrossRef
132.
Salazar A, Pérez-de la Cruz V, Muñoz-Sandoval E, Chavarria V, García Morales MdL, Espinosa-Bonilla A, Sotelo J, Jiménez-Anguiano A, Pineda B. Potential use of nitrogen-doped carbon nanotube sponges as payload carriers against malignant glioma. Nanomaterials. 2021;11(5):1244.PubMedPubMedCentralCrossRef
133.
Perini G, Palmieri V, Ciasca G, D’Ascenzo M, Primiano A, Gervasoni J, De Maio F, De Spirito M, Papi M. Enhanced chemotherapy for glioblastoma multiforme mediated by functionalized graphene quantum dots. Materials. 2020;13(18):4139.PubMedPubMedCentralCrossRef
134.
Perini G, Palmieri V, Friggeri G, Augello A, De Spirito M, Papi M. Carboxylated graphene quantum dots-mediated photothermal therapy enhances drug-membrane permeability, ROS production, and the immune system recruitment on 3D glioblastoma models. Cancer Nanotechnol. 2023;14(1):13.CrossRef
135.
Perini G, Rosa E, Friggeri G, Di Pietro L, Barba M, Parolini O, Ciasca G, Moriconi C, Papi M, De Spirito M. INSIDIA 2.0 high-throughput analysis of 3D cancer models: multiparametric quantification of graphene quantum dots photothermal therapy for glioblastoma and pancreatic cancer. Int J Mol Sci. 2022;23(6):3217.PubMedPubMedCentralCrossRef
136.
Li Z, Zhao C, Fu Q, Ye J, Su L, Ge X, Chen L, Song J, Yang H. Neodymium (3+)-coordinated black phosphorus quantum dots with retrievable NIR/X‐ray optoelectronic switching effect for anti‐glioblastoma. Small. 2022;18(5):2105160.CrossRef
137.
Kaushik NK, Kaushik N, Wahab R, Bhartiya P, Linh NN, Khan F, Al-Khedhairy AA, Choi EH. Cold atmospheric plasma and gold quantum dots exert dual cytotoxicity mediated by the cell receptor-activated apoptotic pathway in glioblastoma cells. Cancers. 2020;12(2):457.PubMedPubMedCentralCrossRef
138.
Iranpour S, Bahrami AR, Saljooghi AS, Matin MM. Application of smart nanoparticles as a potential platform for effective colorectal cancer therapy. Coord Chem Rev. 2021;442:213949.CrossRef
139.
Eugenio M, Campanati L, Müller N, Romão LF, de Souza J, Alves-Leon S, de Souza W, Sant’Anna C. Silver/silver chloride nanoparticles inhibit the proliferation of human glioblastoma cells. Cytotechnology. 2018;70(6):1607–18.PubMedPubMedCentralCrossRef
140.
Householder KT, DiPerna DM, Chung EP, Luning AR, Nguyen DT, Stabenfeldt SE, Mehta S, Sirianni RW. pH driven precipitation of quisinostat onto PLA-PEG nanoparticles enables treatment of intracranial glioblastoma. Colloids Surf B. 2018;166:37–44.CrossRef
141.
Davanzo NN, Pellosi DS, Franchi LP, Tedesco AC. Light source is critical to induce glioblastoma cell death by photodynamic therapy using chloro-aluminiumphtalocyanine albumin-based nanoparticles. Photodiagn Photodyn Ther. 2017;19:181–3.CrossRef
142.
Zhang P, Miska J, Lee-Chang C, Rashidi A, Panek WK, An S, Zannikou M, Lopez-Rosas A, Han Y, Xiao T. Therapeutic targeting of tumor-associated myeloid cells synergizes with radiation therapy for glioblastoma. Proc Natl Acad Sci. 2019;116(47):23714–23.PubMedPubMedCentralCrossRef
143.
Liu P, Huang Z, Chen Z, Xu R, Wu H, Zang F, Wang C, Gu N. Silver nanoparticles: a novel radiation sensitizer for glioma? Nanoscale. 2013;5(23):11829–36.PubMedCrossRef
144.
Meteoglu I, Erdemir A. Genistein and temozolomide-loaded polymeric nanoparticles: a synergistic approach for improved anti-tumor efficacy against glioblastoma. Process Biochem. 2021;110:9–18.CrossRef
145.
Alphandéry E, Idbaih A, Adam C, Delattre J-Y, Schmitt C, Guyot F, Chebbi I. Development of non-pyrogenic magnetosome minerals coated with poly-l-lysine leading to full disappearance of intracranial U87-Luc glioblastoma in 100% of treated mice using magnetic hyperthermia. Biomaterials. 2017;141:210–22.PubMedCrossRef
146.
Patil R, Galstyan A, Sun T, Shatalova ES, Butte P, Mamelak AN, Carico C, Kittle DS, Grodzinski ZB, Chiechi A. Polymalic acid chlorotoxin nanoconjugate for near-infrared fluorescence guided resection of glioblastoma multiforme. Biomaterials. 2019;206:146–59.PubMedPubMedCentralCrossRef
147.
Hettiarachchi SD, Graham RM, Mintz KJ, Zhou Y, Vanni S, Peng Z, Leblanc RM. Triple conjugated carbon dots as a nano-drug delivery model for glioblastoma brain tumors. Nanoscale. 2019;11(13):6192–205.PubMedPubMedCentralCrossRef
148.
Qian M, Du Y, Wang S, Li C, Jiang H, Shi W, Chen J, Wang Y, Wagner E, Huang R. Highly crystalline multicolor carbon nanodots for dual-modal imaging-guided photothermal therapy of glioma. ACS Appl Mater Interfaces. 2018;10(4):4031–40.PubMedCrossRef
149.
Lee C, Hwang HS, Lee S, Kim B, Kim JO, Oh KT, Lee ES, Choi HG, Youn YS. Rabies virus-inspired silica‐coated gold nanorods as a photothermal therapeutic platform for treating brain tumors. Adv Mater. 2017;29(13):1605563.CrossRef
150.
Ran D, Mao J, Shen Q, Xie C, Zhan C, Wang R, Lu W. GRP78 enabled micelle-based glioma targeted drug delivery. J Controlled Release. 2017;255:120–31.CrossRef
151.
Wu C, Xu Q, Chen X, Liu J. Delivery luteolin with folacin-modified nanoparticle for glioma therapy. Int J Nanomed. 2019;14:7515.CrossRef
152.
Zheng S, Cheng Y, Teng Y, Liu X, Yu T, Wang Y, Liu J, Hu Y, Wu C, Wang X. Application of luteolin nanomicelles anti-glioma effect with improvement in vitro and in vivo. Oncotarget. 2017;8(37):61146.PubMedPubMedCentralCrossRef
153.
Yang J, Shi Z, Liu R, Wu Y, Zhang X. Combined-therapeutic strategies synergistically potentiate glioblastoma multiforme treatment via nanotechnology. Theranostics. 2020;10(7):3223.PubMedPubMedCentralCrossRef
154.
Jiang H, Wang C, Guo Z, Wang Z, Liu L. Silver nanocrystals mediated combination therapy of radiation with magnetic hyperthermia on glioma cells. J Nanosci Nanotechnol. 2012;12(11):8276–81.PubMedCrossRef
155.
Ohtake M, Umemura M, Sato I, Akimoto T, Oda K, Nagasako A, Kim J-H, Fujita T, Yokoyama U, Nakayama T, et al. Hyperthermia and chemotherapy using Fe(Salen) nanoparticles might impact glioblastoma treatment. Sci Rep. 2017;7(1):42783.PubMedPubMedCentralCrossRef
156.
Minaei SE, Khoei S, Khoee S, Vafashoar F, Mahabadi VP. In vitro anti-cancer efficacy of multi-functionalized magnetite nanoparticles combining alternating magnetic hyperthermia in glioblastoma cancer cells. Mater Sci Engineering: C. 2019;101:575–87.CrossRef
157.
Hao Y, Zhang B, Zheng C, Ji R, Ren X, Guo F, Sun S, Shi J, Zhang H, Zhang Z. The tumor-targeting core–shell structured DTX-loaded PLGA@ au nanoparticles for chemo-photothermal therapy and X-ray imaging. J Controlled Release. 2015;220:545–55.CrossRef
158.
Kuang J, Song W, Yin J, Zeng X, Han S, Zhao YP, Tao J, Liu CJ, He XH, Zhang XZ. iRGD modified chemo-immunotherapeutic nanoparticles for enhanced immunotherapy against glioblastoma. Adv Funct Mater. 2018;28(17):1800025.CrossRef
159.
Yao J, Feng X, Dai X, Peng G, Guo Z, Liu Z, Wang M, Guo W, Zhang P, Li Y. TMZ magnetic temperature-sensitive liposomes-mediated magnetothermal chemotherapy induces pyroptosis in glioblastoma. Nanomed Nanotechnol Biol Med. 2022;43:102554.CrossRef
160.
Tapeinos C, Marino A, Battaglini M, Migliorin S, Brescia R, Scarpellini A, Fernández CDJ, Prato M, Drago F, Ciofani G. Stimuli-responsive lipid-based magnetic nanovectors increase apoptosis in glioblastoma cells through synergic intracellular hyperthermia and chemotherapy. Nanoscale. 2019;11(1):72–88.CrossRef
161.
Ito A, Shinkai M, Honda H, Kobayashi T. Heat-inducible TNF-α gene therapy combined with hyperthermia using magnetic nanoparticles as a novel tumor-targeted therapy. Cancer Gene Ther. 2001;8(9):649–54.PubMedCrossRef
162.
Babincová N, Sourivong P, Babinec P, Bergemann C, Babincová M, Durdík Š. Applications of magnetoliposomes with encapsulated doxorubicin for integrated chemotherapy and hyperthermia of rat C6 glioma. Z für Naturforschung C. 2018;73(7–8):265–71.CrossRef
163.
Zhang H, Wang T, Liu H, Ren F, Qiu W, Sun Q, Yan F, Zheng H, Li Z, Gao M. Second near-infrared photodynamic therapy and chemotherapy of orthotopic malignant glioblastoma with ultra-small cu 2 – x Se nanoparticles. Nanoscale. 2019;11(16):7600–8.PubMedCrossRef
164.
Pucci C, Marino A, Şen Ö, De Pasquale D, Bartolucci M, Iturrioz-Rodríguez N, di Leo N, de Vito G, Debellis D, Petretto A. Ultrasound-responsive nutlin-loaded nanoparticles for combined chemotherapy and piezoelectric treatment of glioblastoma cells. Acta Biomater. 2022;139:218–36.PubMedCrossRef
165.
Erel-Akbaba G, Carvalho LA, Tian T, Zinter M, Akbaba H, Obeid PJ, Chiocca EA, Weissleder R, Kantarci AG, Tannous BA. Radiation-induced targeted nanoparticle-based gene delivery for brain tumor therapy. ACS Nano. 2019;13(4):4028–40.PubMedPubMedCentralCrossRef
166.
Chen M-H, Liu T-Y, Chen Y-C, Chen M-H. Combining augmented radiotherapy and immunotherapy through a nano-gold and bacterial outer-membrane vesicle complex for the treatment of glioblastoma. Nanomaterials. 2021;11(7):1661.PubMedPubMedCentralCrossRef
167.
Hartshorn CM, Bradbury MS, Lanza GM, Nel AE, Rao J, Wang AZ, Wiesner UB, Yang L, Grodzinski P. Nanotechnology strategies to advance outcomes in clinical cancer care. ACS Nano. 2018;12(1):24–43.PubMedCrossRef
168.
Yang F, Zhao Z, Sun B, Chen Q, Sun J, He Z, Luo C. Nanotherapeutics for antimetastatic treatment. Trends Cancer. 2020;6(8):645–59.PubMedCrossRef
169.
Yasri S, Wiwanitkit V. Nanotechnology in oncology: a concern on its unwanted effects and ethics. J Med Soc. 2018;32(2):81.CrossRef
170.
Singh N, Manshian B, Jenkins GJ, Griffiths SM, Williams PM, Maffeis TG, Wright CJ, Doak SH. NanoGenotoxicology: the DNA damaging potential of engineered nanomaterials. Biomaterials. 2009;30(23–24):3891–914.PubMedCrossRef
171.
Tinkle SS. Nanotechnology: collaborative opportunities for ecotoxicology and environmental health. Environ Toxicol Chem. 2008;27(9):1823.PubMedCrossRef
172.
Shen L, Wang Z, Zhou P. The genetic toxicity and toxicology mechanism of metal nano materials. Chin J Prev Med. 2015;49(9):831–4.
Metadata
Title
New insights into targeted therapy of glioblastoma using smart nanoparticles
Authors
Habib Ghaznavi
Reza Afzalipour
Samideh Khoei
Saman Sargazi
Sakine Shirvalilou
Roghayeh Sheervalilou
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2024
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-024-03331-3

Other articles of this Issue 1/2024

Cancer Cell International 1/2024 Go to the issue

Research

C6orf15 promotes liver metastasis via WNT/β-catenin signalling in colorectal cancer

Research

Identification of TNFRSF21 as an inhibitory factor of osteosarcoma based on a necroptosis-related prognostic gene signature and molecular experiments

Research

IGFBP3 induces PD-L1 expression to promote glioblastoma immune evasion

Review

RNA m6A methylation regulators in liver cancer

Correction

Correction: A novel mechanism by which ACTA2-AS1 promotes cervical cancer progression: acting as a ceRNA of miR-143-3p to regulate SMAD3 expression

Review

PI3K/AKT pathway as a pivotal regulator of epithelial-mesenchymal transition in lung tumor cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits